| Contributing Authors | p. vii |
| Preface | p. xiii |
| Principles of Chemotherapy | |
| Scientific Foundation of Chemotherapy | |
| Scientific Basis of Cancer Chemotherapy | p. 1 |
| Antineoplastic Drug Development | p. 6 |
| Principles of Pharmacology | p. 14 |
| Norton-Simon Hypothesis | p. 23 |
| Drug Resistance | p. 37 |
| Adjuvant Chemotherapy | p. 48 |
| Combination Chemotherapy | p. 69 |
| Combined Modality Therapy | p. 73 |
| Design and Interpretation of Clinical Trials | p. 81 |
| Clinical Trials | p. 89 |
| Hematopoietic Growth Factors | p. 94 |
| Biologic Response Modifiers: Principles of Biotherapy | p. 105 |
| Circadian Timing of Cancer Chemotherapy | p. 114 |
| Routes of Administration | |
| Intraventricular and Intrathecal Therapy | p. 132 |
| Intraperitoneal Chemotherapy | p. 141 |
| Continuous Intravenous Infusion Chemotherapy | p. 144 |
| Intraarterial Therapy | p. 163 |
| Perfusion Therapy | p. 174 |
| Hematopoietic Stem Cell Transplantation | p. 185 |
| Chemotherapeutic Drugs | |
| Covalent DNA-Binding Drugs | p. 192 |
| Antimetabolites | p. 208 |
| Antitumor Antibiotics and Related Compounds | p. 227 |
| Microtubule-Targeting Drugs | p. 252 |
| DNA Topoisomerase II Inhibitors | p. 278 |
| Topoisomerase I-Targeting Drugs | p. 289 |
| Differentiation Agents | p. 304 |
| Hormones | p. 312 |
| L-Asparaginase | p. 323 |
| Investigational Drugs | p. 325 |
| Antibodies | p. 394 |
| Management of Drug Toxicity | |
| Hematologic Complications of Cancer Chemotherapy | p. 399 |
| Oral Toxicity | p. 406 |
| Dermatologic Toxicity | p. 424 |
| Extravasation | p. 432 |
| Hypersensitivity Reactions | p. 436 |
| Ocular Side Effects of Chemotherapy | p. 452 |
| Cardiotoxicity of Chemotherapeutic Drugs | p. 458 |
| Chemotherapy-Associated Lung Injury | p. 468 |
| Gastrointestinal Complications of Chemotherapy | p. 477 |
| Hepatotoxicity of Chemotherapeutic Agents | p. 483 |
| Renal and Electrolyte Abnormalities Due to Chemotherapy | p. 494 |
| Neurotoxicity of Chemotherapy Agents | p. 504 |
| Vascular Toxicity | p. 514 |
| Second Malignancies after Chemotherapy | p. 526 |
| Chemotherapy in Pregnancy | p. 537 |
| Gonadal Complications and Teratogenicity of Cancer Therapy | p. 546 |
| Drug Administration | |
| Central Venous Access for Chemotherapy | p. 559 |
| Risks of Handling Cytotoxic Drugs | p. 566 |
| Patient Education | p. 583 |
| Current Therapy of Specific Solid Tumors | |
| Chemotherapy of Melanoma | p. 596 |
| Chemotherapy of Primary Brain Tumors | p. 602 |
| Chemotherapy of Head and Neck Cancer | p. 610 |
| Chemotherapy of Lung Cancer | p. 626 |
| Chemotherapy of Breast Cancer | p. 647 |
| Chemotherapy of Gastrointestinal Cancer | p. 689 |
| Chemotherapy of Endocrine Tumors | p. 698 |
| Chemotherapy of Genitourinary Cancers | p. 710 |
| Chemotherapy of Gynecologic Cancer | p. 732 |
| Chemotherapy of Sarcomas of Bone and Soft Tissue | p. 760 |
| Chemotherapy of Carcinoma of Unknown Primary Site | p. 778 |
| Chemotherapy of Pediatric Solid Tumors | p. 788 |
| Chemotherapy of Hematologic Malignancies | |
| Chemotherapy of Hodgkin's Disease | p. 795 |
| Chemotherapy of Non-Hodgkin's Lymphoma | p. 810 |
| Chemotherapy of Acute Leukemia in Adults | p. 824 |
| Chemotherapy and Immunotherapy of Chronic Lymphocytic Leukemia and Hairy Cell Leukemia | p. 839 |
| Chemotherapy of the Myelodysplastic Syndromes | p. 849 |
| Management of Chronic Myeloproliferative Disorders and Chronic Myelocytic Leukemia | p. 857 |
| Chemotherapy of Multiple Myeloma and Related Plasma Cell Dyscrasias | p. 865 |
| Appendices | |
| Chemotherapy Programs | p. 876 |
| Common Toxicity Criteria | p. 905 |
| Index | p. 941 |
| Table of Contents provided by Syndetics. All Rights Reserved. |